SEC Comment Letter for ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Feb 8, 2019
ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: Feb. 8, 2019 · CIK: 0001513525 · Accession: 0000000000-19-001637
AI Filing Summary & Sentiment
Reasoning
Letter
February 7, 2019 William Stilley, III President and Chief Executive Officer ADIAL PHARMACEUTICALS, INC. 1001 Research Park Blvd., Suite 100 Charlottesville, VA 22911 Re:ADIAL PHARMACEUTICALS, INC. Draft Registration Statement on Form S-1 Filed January 7, 2019 File No. 377-02455 Dear Mr. Stilley, III: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Todd Schiffman at 202-551-3491 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
February 7, 2019
William Stilley, III
President and Chief Executive Officer
ADIAL PHARMACEUTICALS, INC.
1001 Research Park Blvd.,
Suite 100
Charlottesville, VA 22911
Re:ADIAL PHARMACEUTICALS, INC.
Draft Registration Statement on Form S-1
Filed January 7, 2019
File No. 377-02455
Dear Mr. Stilley, III:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Todd Schiffman at 202-551-3491 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance